Purpose

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.

Condition

Eligibility

Eligible Ages
Between 18 Years and 50 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • 18-50 years of age

Exclusion Criteria

  1. Difficulties seeing a computer screen 2. Anyone currently taking CBD within the last 24 hours. 3. Anyone using any cannabis product within the last 24 hours. 4. Heart problems or heart disease 5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm 6. Are currently pregnant or breast-feeding

Study Design

Phase
Early Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial Assignment
Intervention Model Description
Drug group vs. Placebo group
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)
Masking Description
double blind

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cannabidiol
600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.
  • Drug: Cannabidiol Oral Product
    Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
Placebo Comparator
Placebo
Same number of placebo capsules / participant. One-time dose.
  • Other: Placebo
    Participants will receive a one-time dose of placebo capsules in the form of six capsules.

Recruiting Locations

More Details

Status
Recruiting
Sponsor
University of Connecticut

Study Contact

Robert Astur, PhD
2032369938
robert.astur@uconn.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.